SCHEMBL23926477

SCHEMBL23926477

Cc1cncc(C(=O)Nc2nc3ccc(N)cc3s2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.53
NPC1 O15118 9/20 0.53
SMN1; SMN2 Q16637 7/20 0.53
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 3/20 0.53
ATM Q13315 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
GFER P55789 1/20 0.52
SCD O00767 1/20 0.52
MAPT P10636 4/20 0.52
HTT P42858 3/20 0.52
TP53 P04637 3/20 0.52
USP2 O75604 1/20 0.52
POLB P06746 1/20 0.52
OPRK1 P41145 1/20 0.51
GLA P06280 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23926482 0.84 NPC1 (0.65) RAB9ANPC1SMN1; SMN2ALDH1A1RXFP1
SCHEMBL23926494 0.84 MAPT (0.70) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL22130268 0.82 NPC1 (0.71) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL31219253 0.82 NPC1 (0.71) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL23926513 0.81 NPC1 (0.59) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
Cyanide SCHEMBL22130089 0.80 RAB9A (0.46) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL23926531 0.79 NPC1 (0.61) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL24706340 0.78 RAB9A (0.45) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL22130185 0.78 NPC1 (0.64) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL31219264 0.78 NPC1 (0.64) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
CN-113727972-A Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof 韩国科学技术研究院 2021-11-30 CN disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 RAB9A 1131/4885NPC1 1264/4885SMN1; SMN2 4531/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT RAB9A 2732/4885NPC1 3755/4885SMN1; SMN2 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.